Pre-clinical companies

Syncona’s pre-clinical portfolio companies are developing their pipelines, proprietary platforms and progressing towards entering clinical trials.

Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: chronic renal diseases, melanoma, multiple myeloma, heart attacks and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.

Portfolio in numbers

Unless stated all financials at 31 March 2025

£154m

Value of pre-clinical portfolio

6

No. of companies

14

Portfolio company Board seats

Our pre-clinical portfolio companies